Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail
Regulatoryexon-skippersNegative
AI Analysis
Summary
Sarepta is pursuing conversion of accelerated approval to full FDA approval for its exon-skipping therapies for Duchenne muscular dystrophy, with an FDA decision expected in early 2027, despite the drugs failing to improve motor function in a confirmatory trial.
Clinical Trial Data
Primary Endpoint
Not Met
Outcome Details
Seeking to convert accelerated approval to full approval despite confirmatory trial failure
Importance:8/10
Sentiment:
-0.30
accelerated approvalconfirmatory trial failureDuchenne muscular dystrophyFDA decisionexon-skipping
Related Companies
Read the original article
Published by BioSpace on July 1, 2026 11:56 AM